

1. Record Nr.	UNINA9910821051703321
Titolo	Nonclinical assessment of abuse potential for new pharmaceuticals // edited by Carrie G. Markgraf, Thomas J. Hudzik and David R. Compton
Pubbl/distr/stampa	London, [England] ; ; San Diego, California : , : Academic Press, an imprint of Elsevier, , 2015 ©2015
ISBN	0-12-420216-0 0-12-420172-5
Descrizione fisica	1 online resource (321 p.)
Disciplina	362.29
Soggetti	Drug abuse Drugs - Overdose Opioids - Overdose
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di contenuto	Front Cover; Nonclinical Assessment of Abuse Potential for New Pharmaceuticals; Copyright; CONTENTS; CONTRIBUTORS; FOREWORD; PREFACE; ACKNOWLEDGMENTS; Chapter 1 - Nonclinical Assessment of Abuse Potential for New Pharmaceuticals in a Regulatory Space; 1. TERMINOLOGY; 2. ANIMAL MODELS OF ABUSE POTENTIAL; 3. REGULATION OF DRUGS OF ABUSE; 4. SCHEDULING; 5. SUMMARY; REFERENCES; Chapter 2 - Neurochemistry of Abuse Liability Assessment and Primary Behavioral Correlates; 1. INTRODUCTION; 2. REWARD SYSTEM; REFERENCES; Chapter 3 - Rat Self-Administration; 1. INTRODUCTION; 2. REGULATORY ISSUES 3. THE OPERANT CHAMBER SET UP 4. THE TRAINING; 5. THE DRUG CONTINGENCIES; 6. THE TESTING; 7. DOSE-RESPONSE RELATIONSHIPS; 8. MAINTENANCE DRUG; 9. GENDER; 10. LIMITED VERSUS UNLIMITED ACCESS TO DRUG DURING TRAINING; 11. RESPONSE TOPOGRAPHY; 12. REINFORCING EFFICACY; 13. CONCLUSION; REFERENCES; Chapter 4 - Nonhuman Primate Self-Administration in Assessments of Abuse Potential; 1. ASSESSMENT OF ABUSE POTENTIAL IN LABORATORY ANIMALS; 2. RATIONALE FOR USING NONHUMAN PRIMATES IN ASSESSMENTS OF ABUSE POTENTIAL; 3. STUDYING DRUG SELF-

## ADMINISTRATION IN NONHUMAN PRIMATES

4. STUDYING DRUG DEPENDENCE IN NONHUMAN PRIMATES  
5. CONCLUSIONS AND RECOMMENDATIONS; ACKNOWLEDGMENTS; REFERENCES; Chapter 5 - Assessing Physical Dependence; 1. INTRODUCTION; 2. DEFINITIONS; 3. NEUROBIOLOGY OF WITHDRAWAL; 4. WITHDRAWAL: PRECIPITATED AND NONPRECIPITATED; 5. USE OF POSITIVE AND NEGATIVE CONTROLS IN THE WITHDRAWAL TEST; 6. ANIMAL MODEL OF NONPRECIPITATED WITHDRAWAL; 7. GENERAL CONSIDERATIONS; 8. GOOD LABORATORY PRACTICES; 9. REGULATORY GUIDANCE AND GLOBAL REGULATORY FRAMEWORK; 10. TIMELINES; 11. PHYSICAL DEPENDENCE TESTING OF LARGE MOLECULES  
12. PHYSICAL DEPENDENCE TESTING IN HUMANS  
13. CONCLUSIONS; LIST OF ABBREVIATIONS; REFERENCES; Chapter 6 - Drug Discrimination: Use in Preclinical Assessment of Abuse Liability; 1. FROM STATE DEPENDENCY TO DRUG DISCRIMINATION: A BRIEF HISTORY; 2. METHODOLOGY; 3. SOFTWARE; 4. TRAINING DRUGS; 5. DRUG DISCRIMINATION: TRAINING AND TESTING; 6. DATA INTERPRETATION: LEVELS OF GENERALIZATION; 7. THE DISCRIMINATIVE EFFECT; 8. TIME COURSE DETERMINATION; 9. PHARMACOKINETICS; 10. STRATEGIC PLACEMENT OF DRUG DISCRIMINATION IN THE ABUSE LIABILITY ASSESSMENT TOOLBOX  
11. DRUG DISCOVERY AND DEVELOPMENT STRATEGIC USE OF DRUG DISCRIMINATION  
REFERENCES; Chapter 7 - Conditioned Place Preference as a Preclinical Model for Screening Pharmacotherapies for Drug Abuse; 1. INTRODUCTION; 2. BASIC PRINCIPLES OF CONDITIONED PLACE PREFERENCE; 3. APPLICATION OF CONDITIONED PLACE PREFERENCE TO MEDICATION DEVELOPMENT; 4. RECENT FINDINGS; 5. CONCLUSION; REFERENCES; Chapter 8 - Utility of Intracranial Self-Stimulation in the Assessment of the Abuse Liability of New Pharmaceuticals; 1. INTRODUCTION

---